학술논문
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
Document Type
Journal
Author
Pistilli, Barbara; Wildiers, Hans; Hamilton, Erika Paige; Ferreira, Ana Alexandra; Dalenc, Florence; Vidal, Maria; Gavila, Joaquin; Goncalves, Anthony; Murias, Carmen; Mouret-Reynier, Marie-Ange; Canon, Jean-Luc Re; Bazan, Fernando; Ladoire, Sylvain; Sirulnik, L. Andres; Bekradda, Mohamed; Bol, Kees; Stalbovskaya, Viktoriya; Murat, Anastasia; Ford, Jim; Bidard, Francois Clement
Source
Subject
Language
English
ISSN
15277755